TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04259229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet -- Mushrooms
Description: During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The mushroom group will consume 0.5 cups/day of cooked mushrooms (white button mushrooms and yellow oyster mushrooms on 4 and 3 days/week, respectively). All foods will be provided to subjects during the intervention to achieve the desired eating pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet -- Control
Description: During the 2-week baseline period all participants will consume their usual, unrestricted self-chosen diets. During intervention weeks 1-8, all participants will consume the same Mediterranean-style diet, rich in fruits and seafoods and lower in dairy, designed to meet their estimated energy needs. The control group will not consume mushrooms at any point. All foods will be provided to subjects during the intervention to achieve the desired eating pattern.
Study: NCT06004726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School-based Substance abuse Prevention Programme (SSPP)
Description: Module 1 :Introduction~* Orientation about Training Programme using PowerPoint slides~* Psychoeducation and Video Assisted Teaching to enhance awareness of substance abuse.~* Distribution of informational booklet on basics about substance abuse~Module 2:~* Role play to develop a positive attitude towards the prevention of substance abuse.~* Case-based scenario to increase resistance to peer pressure.~* Demonstration of drug refusal techniques.~Module3:• Storytelling on Life skills Training Components (Problem solving, Emotion Management)~Module 4:• Demonstration of Life skills training components (Communication skills, Decision making skills, Creative thinking skills, Stress Management strategies )
Study: NCT05473169

Intervention type: DEVICE
Intervention: Videofluoroscopy
Description: Swallowing assessment

Intervention type: DEVICE
Intervention: Videofluoroscopy
Description: Swallowing assessment
Study: NCT06246032

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified feeding Protocol
Description: Initiation of feeding (fixed): 10cc/kg~Advancement based on birthweight (fixed):~\<750g: 15cc/kg/d 750-999g: 20cc/kg/d 1000-1249g: 25cc/kg/d 1250-1499g: 25cc/kg/d 1500-1749g: 35cc/kg/d 1750-2000g: 35cc/kg/d~Starting Human milk fortification when feed reach at 70cc/kg/d
Study: NCT04745026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: GWP42003-P oral solution (100 milligrams per milliliter \[mg/mL\] cannabidiol \[CBD\] in sesame oil with anhydrous ethanol, ethanol \[10% v/v\] sweetener \[sucralose\], and strawberry flavoring), administered twice a day (morning and evening)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo to match GWP42003-P oral solution containing sesame oil with anhydrous ethanol, sweetener (sucralose), strawberry flavoring, and beta carotene, administered twice a day (morning and evening)
Study: NCT05485909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: For multiple intrahepatic lesions, select 1 to 2 lesions for radiofrequency ablation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib and Toripalimab Combination
Description: Toripalimab 200 mg, iv drip, d1, d15, q4w, Regorafenib 80mg, po, d1-d21, Q4w.
Study: NCT04913896

Intervention type: DRUG
Intervention: PD-1 inhibitor
Description: SOX regimen for 3 cycles and/or PD-1 inhibitor before surgery
Study: NCT06411366

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Follistatin plasmid
Description: Follistatin-344 plasmid
Study: NCT05941221

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pericapsular nerve group (PENG) block
Description: patients will receive PENG block through ultrasound. The regional block was performed with the patient in the supine position. A curvilinear low-frequency ultrasound probe (2-5MHz) was initially placed in a transverse plane over the AIIS and then aligned with the pubic ramus by rotating the probe counterclockwise approximately 45 degrees. In this view, the IPE, the iliopsoas muscle and tendon, the femoral artery, and pectineus muscle were observed . A 22-gauge, 80-mm needle was inserted from lateral to medial in an in-plane approach to place the tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. Following negative aspiration, the local anesthetic solution was injected in 5-mL increments while observing for adequate fluid spread in this plane for a total volume of 20 mL bupivacaine 0.25%.
Study: NCT06381063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pain management
Description: o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pain management
Description: o Pain management in both arms Intraoperative time: intravenous ketamine 0.5 mg kg-1, intravenous dexamethasone 8 mg Postoperative time: paracetamol 1 g every 6 hours a day, nefopam 20 every 8 hours a day, patient control analgesia with morphine or oxycontin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoprofen
Description: Ketoprofen 100 mg twice a day, during 48 after surgery, intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLacebo
Description: Placebo twice a day, during 48 h after surgery, intravenous administration
Study: NCT05475353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asyncronized Exercise
Description: This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Syncronized Exercise
Description: This group will be informed about ergonomics and protective exercises for the musculoskeletal system with an online seminar. Then, participants will complete the 6 weeks of exercise training at an online video conference program two times a week under the physiotherapist's supervise.
Study: NCT04508998

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood tests including genotyping
Description: Blood tests for alternative SNPs altering levels of ET-A receptor expression; blood will be further analysed for endothelin receptor mRNA and other plasma peptides important in the endothelin signalling pathway

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise Tolerance Test
Description: Treadmill exercise test using the Bruce protocol
Study: NCT05991739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)
Description: FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Familias Inmigrantes Empoderándose contra eStrés Tomando Acción (FIESTA)
Description: FIESTA is a 10-session, group intervention led by community health workers that offers strategies related to individual stress management, family coping and communication, and community navigation.
Study: NCT05209945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vibration
Description: whole-body vibration, heel and soleus tendon vibrations were applied to the human body
Study: NCT03629093

Intervention type: DRUG
Intervention: General Anesthetics
Description: General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.

Intervention type: DRUG
Intervention: General Anesthetics
Description: General anesthesia required for surgery procedures or diagnostic interventions using either intravenous or inhalation anesthetics, or both.
Study: NCT05751382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surefil one
Description: Restorative material (Dentsply Sirona). Used for direct restoration of class V NCCL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Pearl
Description: Restorative material. Traditional paste composite employed in combination with iBond universal adhesive.
Study: NCT05921890

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS3-007 oral liquid
Description: The dosage was calculated according to body weight, once a day or twice a day.
Study: NCT06170866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially supported physical activity
Description: Use of a culturally and linguistically tailored intervention that uses mobile health technology plus social support to increase engagement in physical activity in the management of Parkinson´s disease.
Study: NCT04996238

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood and nasal fluid sampling before and after COVID-19 vaccination
Description: Blood and nasal fluid sampling take place just before the first COVID-19 vaccination and at 14-30 days after the second dose with the same vaccine. Sampling will be repeated at 6 months after the second vaccination, at 14-30 days after the third vaccination and at 6 months after the third vaccination. At all moments, a questionnaire is filled in.
Study: NCT05770726

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics administration
Description: A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics administration
Description: A total of 10 grams of probiotics was administered in both group, but the routes were different. One group were per colonoscopic spray, and the other was per oral.
Study: NCT06486610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fish-shaped nebulizer and fish-shaped toy
Description: In order to reduce the child's fear and anxiety, it is planned to apply inhalation therapy using a nebulizer with a red fish figure and an amigurumi toy with a red fish figure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silent nebulizer
Description: It is planned to apply inhalation therapy using a silent nebulizer to reduce the child's fear and anxiety.
Study: NCT04770623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: patients with gastric cancer who have disease progression after first line treatment will receive the test protocol and evaluated for efficacy and survival
Study: NCT04359641

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoMET Display
Description: Display and presentation of predictive monitoring score CoMET
Study: NCT04931667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorecivivint
Description: Healthcare professional-administered intra-articular (IA) injection into one or both knees as clinically indicated. Bilateral injections of 0.07 mg of LOR are allowed. IA injection performed on Day 1. Additional IA injections of LOR to same knee (with at least a 6 month separation) between Day 1 and Month 33.
Study: NCT04845165

Intervention type: OTHER
Intervention: Biopsy
Description: Biopsy of subcutaneous adipose tissue
Study: NCT05823090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light box (Carex DayLight Classic Model)
Description: The active light box is a white fluorescent 4000 Kelvin unit that emits 10,000 lux and measures 33cm x 40cm. The placebo box emits 50 lux dim red light and appears identical to the active unit. Subjects were instructed to position themselves 30-36 cm from the box with their faces fully exposed to the light. The actigraphy device is a Phillips Spectrum Plus Actigraphy watch which collects activity level and sleep information along with multiple light measurements and wearer adherence.
Study: NCT05328141

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bread and butter
Description: A bread with butter meal without insect biomass with FeSO4 (isotopic iron 54)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: X.gideon
Description: Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: X.gideon with ascorbic acid
Description: Intrinsically labelled (57Fe) or non labelled X.gideon flour mixed with butter and sugar meal with FeSO4 (extrinsic label, isotopic iron 58) and ascorbic acid
Study: NCT05856045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF(proprioceptive neuromuscular facilitation exercises)
Description: PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session was given to patients. 45 mins session/each day for 6 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBBT (pertubation based balance training)
Description: Perturbation-based balance training (PBT) is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Pertubations are given by therapist in unexpected directions to challenge patients reactive balance. In this study pertubations will be given manually and on treadmill by a harness system.~daily 45 mins of exercise session of pertuations divided into double leg foam roller, wobble board exercises and pertubations on treadmill were performed for total 8 weeks and 6 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF and PBBT intervention group
Description: proprioceptive neuromuscular exercises, pertubation based balance training along with conventional physiotherapy exercises were given for 8 weeks and 6 days per week for around 45 mins.
Study: NCT05511597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split-belt treadmill training
Description: Split-belt walking with various speed ratios between the two legs, applied with random-block practice

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Split-belt treadmill training
Description: Split-belt walking with various speed ratios between the two legs, applied with random-block practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Complex task practice
Description: Overground gait flexibility training with added cognitive tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static balance exercise
Description: Mindfulness and breathing combined with static balance exercises
Study: NCT05948748

Intervention type: PROCEDURE
Intervention: foot surgery
Description: minimally invasive osteoarticular foot surgery
Study: NCT04908748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esflurbiprofen Hydrogel Patch
Description: Esflurbiprofen is a cyclooxygenase (COX) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esflurbiprofen Hydrogel Patch
Description: Esflurbiprofen is a cyclooxygenase (COX) inhibitor
Study: NCT05733572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6467
Description: drug eyedrops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo eyedrops
Study: NCT06056388

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straumann BLX implant
Description: Implant system with a deep fixture thread depth.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Straumann BLT implant
Description: Implant system with a regular fixture thread depth.
Study: NCT05903326

Intervention type: OTHER
Intervention: Dexmedetomidine
Description: this was an observational study only based on a change of practice
Study: NCT05201690

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VV116 200 mg Group
Description: Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 200 mg Group
Description: Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VV116 400mg Group
Description: Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 400mg Group
Description: Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VV116 600mg Group
Description: Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV116 600mg Group
Description: Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;
Study: NCT05897398

Intervention type: OTHER
Intervention: Data collection
Description: Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.

Intervention type: OTHER
Intervention: Data collection
Description: Data collected at initiation, 6 months and 12 months of WEGOVY® treatment will be retrospectively extracted from the WEGOVY® ATU/AP2 eCRF.

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling for routine care (max 15mL) and constitution of a plasma bank (28 mL)

Intervention type: OTHER
Intervention: Questionnaires
Description: Completion of questionnaires for the entire cohort:~To assess hyperphagia and eating behaviour: BES, DEBQ and Hunger Score questionnaire To assess physical activity: short IPAQ To assess sleep behaviour: MCTQ To assess quality of life: EQ5D5L To assess digestive system disorders: GIQLI To assess anxiety and depression: HAD
Study: NCT06526962

Intervention type: DEVICE
Intervention: 5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser
Description: Outpatient hysteroscopic polypectomy

Intervention type: DEVICE
Intervention: 5Fr hysteroscopic bipolar electrode or conical optical 5Fr fibers for dual wave-length diode laser
Description: Outpatient hysteroscopic polypectomy
Study: NCT06395857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual arts-based intervention
Description: This visual arts-based intervention is grounded on Bandura's Self-Efficacy Theory. It consists of four weekly group and face-to-face sessions delivered by a qualified facilitator. The contents of the intervention involve structured visual art-making activity, group discussion, and workbook assistance.
Study: NCT05113056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acutus Medical Pulsed Field Ablation System
Description: All subjects will be treated using the Acutus Medical Pulsed Field Ablation System (PFA System) to treat their atrial fibrillation.
Study: NCT04940455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational digital platforms
Description: The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational digital platforms
Description: The digital educational platforms will be implemented through games of questions and answers, simulated cases sent via google forms about the nurse's performance in a critical care unit facing the patient with signs and symptoms of sepsis. The questions in the games will aim to develop clinical judgment and quick decision-making in nursing students in order not to compromise the health care of the patient in sepsis.
Study: NCT04818242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM with GTS
Description: CGM sensor will be placed after consent. Glucose values obtained from the CGM sensor will be sent to the CGM transmitter by Bluetooth technology and Dexcom Share2 software application to a smart phone that serves as an intermediate-transmitting (routing) device. Glucose values from the smart phone will be transmitted wirelessly to a table computer (I-Pad) using the Dexcom Follow application. Information on the CGM will activate an alarm in case of hypoglycemia or hyperglycemia events. Hypoglycemia alarm will be set to \< 85 mg/dl (for prevention for low blood glucose levels). Nursing staff will be instructed to provide 15 grams of carbohydrates in response to a hypoglycemia alarm.The hyperglycemia alarm will be set at 300 mg/dl. If this occurs, the nursing staff will assess clinical status and perform a POC glucose testing to confirm glucose values. If blood glucose (BG) \> 300 mg/dl, nursing staff will communicate the high glucose value to the primary care team.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: POC Blood Glucose Test + Blinded CGM
Description: Point of Care (POC) testing before meals and bedtime (standard of care). For the control group, participants will also get a CGM sensor (blinded CGM). CGM alarms are turned off, however if the POC is found to be between \<80 mg/dl by POC, 15 grams of carbohydrates will be given as a preventive measurement for hypoglycemia (standard of care).
Study: NCT04791553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Cenobamate (YKP3089) is a small molecule approved in the United States (US) for the treatment of partial onset seizures (POS) in adult patients.
Study: NCT05893056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation is performed under US or CT guidance per Investigator decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: a PD-1 immune check inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib capsules
Study: NCT06121466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abdominal wall injections with lidocaine 2%
Description: Injections will be administered for patient who are identified as having abdominal wall pain.